Clinical trials: Recurrent Head and Neck Carcinoma
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC
This study is a single center, randomized controlled, prospective phase II clinical trial to evaluate the efficacy and safety of cetuximab combined with dalpicilib compared to cetuximab monotherapy in patients with HPV-negative…
- Trial name
- NCT06935188
- Testing
- Dalpicilib combined with cetuximab, cetuximab
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Nasopharyngeal Carcinoma
Maintenance Treatment of Apatinib in Nasopharyngeal Carcinoma
The study is to evaluate the efficacy and safety of Apatinib for later treatment of patients(after second-line treatment for locally recurrent or metastatic nasopharyngeal carcinoma), including overall survival (OS), distant…
- Trial name
- NCT03130270
- Testing
- Apatinib mesylate tablet
- Where
- 4 sites in China
- Volunteers
- 29 people
- Sponsor
- Guilin Medical University, China
Head and Neck Cancer, Lung Cancer
Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Conditions
- Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00006036
- Testing
- cisplatin, lurtotecan liposome
- Where
- 3 sites in Canada
- Volunteers
- 14 people
- Sponsor
- NCIC Clinical Trials Group
Effect of Drug
Docetaxel/Pembrolizumab in Head and Neck Squamous Cell Carcinoma
Pembrolizumab monotherapy and platinum-based chemotherapy in the combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) have been widely used in daily clinical practice based…
- Trial name
- NCT05252429
- Testing
- Docetaxel, Pembrolizumab
- Where
- Japan
- Volunteers
- 27 people
- Sponsor
- Hokkaido University Hospital
Head and Neck Cancer
Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy
Treatment of recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) after progression to first line EXTREME-type treatment in patients undergoing maintenance treatment with cetuximab.
- Trial name
- EXTAX (NCT03887442)
- Testing
- Paclitaxel, Cetuximab + Paclitaxel
- Volunteers
- 17 people
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Squamous Cell Carcinoma of the Head and Neck
A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck
The investigators will perform a randomized phase II study to investigate if the addition of cetuximab to MTX is beneficial for the patient.
- Trial name
- COMMENCE (NCT02054442)
- Testing
- Cetuximab, Methotrexate
- Where
- 8 sites in Netherlands
- Volunteers
- 52 people
- Sponsor
- Radboud University Medical Center
Adenoid Cystic Carcinoma of the Head and Neck
All-trans Retinoic Acid (ATRA) in the Treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck
This is a prospective, open-label, randomized controlled clinical intervention study to evaluate the efficacy and safety of all-trans retinoic acid (ATRA) in treating patients with recurrent metastatic adenoid cystic carcinoma of…
- Trial name
- Aplus (NCT04433169)
- Testing
- All-trans Retinoic Acid, VEGFR inhibitor, Chemotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Esophageal Squamous Cell Carcinoma (ESCC)
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
The purpose of this study is to evaluate the efficacy and safety of tislelizumab as first line treatment in combination with chemotherapy in participants with advanced unresectable/metastatic esophageal squamous cell carcinoma…
- Trial name
- NCT03783442
- Testing
- Cisplatin, Oxaliplatin, Fluorouracil (5-FU)
- Where
- 124 sites in United States, Australia and 14 more
- Volunteers
- 649 people
- Sponsor
- BeiGene
Esophageal Squamous Cell Carcinoma
Concurrent Radiotherapy and Weekly Chemotherapy of PF for Postoperative Locoregional Recurrence of Esophageal Cancer
The purpose of this study is to evaluate the efficacy and toxicity of radiotherapy concurrently with weekly chemotherapy of 5-FU and cisplatin in patients with postoperative locoregional recurrence of esophageal squamous cell…
- Trial name
- NCT02325986
- Testing
- fluorouracil, Cisplatin, Intensity-modulated radiation therapy
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer
Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer
Participant with squamous cell cancer of head and neck are invited to participate in this study. In this study the investigators will be Inserting the gene for interleukin-12 into a person's cancer cells with the anticipation to…
- Trial name
- NCT00004070
- Testing
- IL-12
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Dana-Farber Cancer Institute
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Fixed dose NT219 weekly plus pembrolizumab every 3 weeks or cetuximab weekly to be continued until progression, unacceptable toxicity, or investigator or participant decision.
- Trial name
- NCT06919666
- Testing
- NT219
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- University of Colorado, Denver
HNSCC
A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants
This is a multicenter, open-label, Phase II clinical study to assess the efficacy, safety, tolerability, PK characteristics, and immunogenicity of SKB571 in participants with recurrent or metastatic HNSCC.
- Trial name
- NCT07668154
- Testing
- SKB571, Pembrolizumab, carboplatin
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This randomized phase III trial studies chemotherapy to see how well it works with or without bevacizumab in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or that has spread to other…
- Conditions
- Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma
- Trial name
- NCT00588770
- Testing
- Bevacizumab, Carboplatin, Cisplatin
- Where
- 779 sites in United States, Puerto Rico and 1 more
- Volunteers
- 403 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma
Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery
This phase I/II trial studies the side effects and best dose of olaparib when given together with ramucirumab and how well they work in treating patients with gastric or gastroesophageal junction cancer that has spread to other…
- Conditions
- Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Carcinoma
- Trial name
- NCT03008278
- Testing
- Olaparib, Ramucirumab
- Where
- 32 sites in United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Neoplasms, Carcinoma, Squamous Cell
BIBW 2992 (Afatinib) in Head & Neck Cancer
The primary objective of this study is to explore the efficacy of BIBW 2992 compared with cetuximab (Erbitux) in patients with metastatic or recurrent head and neck cancer after failure of platinum-containing therapy.
- Trial name
- NCT00514943
- Testing
- BIBW 2992, Cetuximab
- Where
- 36 sites in United States, Belgium and 2 more
- Volunteers
- 124 people
- Sponsor
- Boehringer Ingelheim
Head and Neck Cancer, Long-term Effects Secondary to Cancer Therapy in Adults
Side Effects of High-Dose Intensity-Modulated Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer
RATIONALE: Tests that measure how much saliva is made, hearing, swallowing, voice function, and quality of life may improve the ability to plan treatment for patients with advanced head and neck cancer and may help doctors find…
- Conditions
- Head and Neck Cancer, Long-term Effects Secondary to Cancer Therapy in Adults, Oral Complications of Radiation Therapy, Radiation Toxicity
- Trial name
- NCT00415025
- Testing
- adjuvant therapy, management of therapy complications, quality-of-life assessment
- Volunteers
- 20 people
- Sponsor
- University of Wisconsin, Madison
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer
This phase I trial evaluates the best dose, possible benefits and/or side effects of combination therapy with elimusertib (BAY 1895344), stereotactic body radiation, and pembrolizumab in treating patients with head and neck…
- Conditions
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Cutaneous Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04576091
- Testing
- Biospecimen Collection, Computed Tomography, Elimusertib
- Where
- 11 sites in United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Adrenocortical Carcinoma, Brain and Central Nervous System Tumors
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as cisplatin and doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Estrogen can stimulate the growth of tumor cells.
- Conditions
- Adrenocortical Carcinoma, Brain and Central Nervous System Tumors, Head and Neck Cancer, Liver Cancer
- Trial name
- NCT00002608
- Testing
- cisplatin, doxorubicin hydrochloride, tamoxifen citrate
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Ottawa Regional Cancer Centre
Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma
A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma
This is a multi-center, open-label, phase 1 dose escalation and expansion study evaluating the safety, anti-tumor effect, and immunogenicity of CUE-101 as monotherapy treatment in second line or CUE-101 Combination Therapy with…
- Conditions
- Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Carcinoma
- Trial name
- NCT03978689
- Testing
- CUE-101, KEYTRUDA®, Pembrolizumab
- Where
- 17 sites in United States
- Volunteers
- 80 people
- Sponsor
- Cue Biopharma
Recurrent Head and Neck Squamous Cell Carcinoma
Anti-PD-1 Therapy in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
The goal of this clinical trial is to determine whether a perioperative PD-1 antibody-based treatment strategy, consisting of neoadjuvant PD-1 antibody plus chemotherapy followed by adjuvant PD-1 antibody after surgery, improves…
- Trial name
- neo-Recur (NCT07751289)
- Testing
- Neoadjuvant PD-1 antibody plus chemotherapy, surgery, Adjuvant PD-1 antibody
- Volunteers
- 217 people
- Sponsor
- Yanjie Zhang, MD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.